375 related articles for article (PubMed ID: 20001264)
41. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group.
Arevalo JF; Garcia-Amaris RA; Roca JA; Sanchez JG; Wu L; Berrocal MH; Maia M;
J Cataract Refract Surg; 2007 Dec; 33(12):2098-105. PubMed ID: 18053911
[TBL] [Abstract][Full Text] [Related]
42. intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group.
Wu L; Hernandez-Bogantes E; Roca JA; Arevalo JF; Barraza K; Lasave AF
Retina; 2011 Feb; 31(2):298-303. PubMed ID: 21099452
[TBL] [Abstract][Full Text] [Related]
43. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
44. Comparison between intravitreal and orbital floor triamcinolone acetonide after phacoemulsification in patients with endogenous uveitis.
Roesel M; Tappeiner C; Heinz C; Koch JM; Heiligenhaus A
Am J Ophthalmol; 2009 Mar; 147(3):406-12. PubMed ID: 19054496
[TBL] [Abstract][Full Text] [Related]
45. [Macular oedema and intravitreal triamcinolone injections].
Gunnlaugsdóttir E; Oehman DO; Gunnarsdóttir SG; Stefánsson E
Laeknabladid; 2006 Dec; 92(12):847-57. PubMed ID: 17206015
[TBL] [Abstract][Full Text] [Related]
46. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.
Rodrigues MW; Cardillo JA; Messias A; Siqueira RC; Scott IU; Jorge R
Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):479-490. PubMed ID: 31873786
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation.
Cakir M; Dogan M; Bayraktar Z; Bayraktar S; Acar N; Altan T; Kapran Z; Yilmaz OF
Retina; 2008 Mar; 28(3):465-72. PubMed ID: 18327140
[TBL] [Abstract][Full Text] [Related]
48. Features of optical coherence tomography are predictive of visual outcomes after intravitreal bevacizumab injection for diabetic macular edema.
Roh MI; Kim JH; Kwon OW
Ophthalmologica; 2010; 224(6):374-80. PubMed ID: 20453545
[TBL] [Abstract][Full Text] [Related]
49. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion.
Gregori NZ; Gaitan J; Rosenfeld PJ; Puliafito CA; Feuer W; Flynn HW; Berrocal AM; Al-Attar L; Dubovy S; Smiddy WE; Schwartz SG; Lee WH; Murray TG
Retina; 2008 Oct; 28(9):1325-37. PubMed ID: 19430392
[TBL] [Abstract][Full Text] [Related]
50. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
51. Initial macular thickness and response to treatment in diabetic macular edema.
Soheilian M; Ramezani A; Yaseri M; Mirdehghan SA; Obudi A; Bijanzadeh B
Retina; 2011 Sep; 31(8):1564-73. PubMed ID: 21451442
[TBL] [Abstract][Full Text] [Related]
52. Intravitreal Bevacizumab with or without triamcinolone for refractory diabetic macular oedema.
Synek S; Veselý P
Coll Antropol; 2011 Sep; 35(3):841-5. PubMed ID: 22053565
[TBL] [Abstract][Full Text] [Related]
53. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial.
Ahmadieh H; Ramezani A; Shoeibi N; Bijanzadeh B; Tabatabaei A; Azarmina M; Soheilian M; Keshavarzi G; Mohebbi MR
Graefes Arch Clin Exp Ophthalmol; 2008 Apr; 246(4):483-9. PubMed ID: 17917738
[TBL] [Abstract][Full Text] [Related]
54. Diabetic macular edema before and after intravitreal triamcinolone injection.
Ramezani A; Tabatabaie H; Ahmadieh H
Korean J Ophthalmol; 2007 Jun; 21(2):95-9. PubMed ID: 17592240
[TBL] [Abstract][Full Text] [Related]
55. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.
Tao Y; Hou J; Jiang YR; Li XX; Jonas JB
Eye (Lond); 2010 May; 24(5):810-5. PubMed ID: 19696805
[TBL] [Abstract][Full Text] [Related]
56. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.
Cardillo JA; Melo LA; Costa RA; Skaf M; Belfort R; Souza-Filho AA; Farah ME; Kuppermann BD
Ophthalmology; 2005 Sep; 112(9):1557-63. PubMed ID: 16019075
[TBL] [Abstract][Full Text] [Related]
57. Intravitreal bevacizumab for treatment of uveitic macular edema.
Cordero Coma M; Sobrin L; Onal S; Christen W; Foster CS
Ophthalmology; 2007 Aug; 114(8):1574-1579.e1. PubMed ID: 17363060
[TBL] [Abstract][Full Text] [Related]
58. [Prognostic factors for visual outcome after intravitreal drug therapy for chronic diabetic macular oedema].
Guthoff R; Schrader W; Hennemann K; Meigen T; Göbel W
Klin Monbl Augenheilkd; 2011 May; 228(5):468-72. PubMed ID: 20597042
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of intraoperative intravitreal injection of triamcinolone acetonide injection after phacoemulsification in cases of uveitic cataract.
Dada T; Dhawan M; Garg S; Nair S; Mandal S
J Cataract Refract Surg; 2007 Sep; 33(9):1613-8. PubMed ID: 17720079
[TBL] [Abstract][Full Text] [Related]
60. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
